Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.53 |
| ▸ | CTSS | P25774 | 8/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 6/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164038 | 0.84 | CTSK (0.62) | CTSKCTSSCA5AMMP13CA1 | |
| SCHEMBL7816028 | 0.80 | CA5A (0.56) | CTSKCTSSCA5AMMP13CA1 | |
| SCHEMBL5934588 | 0.79 | CTSK (0.63) | CTSKCTSSCA5AMMP13CA1 | |
| SCHEMBL5934591 | 0.75 | CASP1 (0.56) | CTSKCTSSCA5AMMP13CA1 | |
| SCHEMBL7163920 | 0.75 | TARS1 (0.54) | CTSKCTSSMMP13CA1 | |
| SCHEMBL8823885 | 0.73 | CTSK (0.67) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL7815915 | 0.73 | CTSK (0.55) | CTSKCTSSCA5AMMP13CTSL | |
| SCHEMBL568976 | 0.73 | MMP13 (0.59) | CTSKCTSSMMP13CA1 | |
| SCHEMBL569735 | 0.73 | MMP13 (0.59) | CTSKCTSSMMP13CA1 | |
| SCHEMBL7165081 | 0.72 | CTSK (0.51) | CTSKCTSSCA5ACA1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSS 8/4885CA5A 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.